Importantly, PDPN inhibition counteracts immune escape in melanoma through the downregulation of immune checkpoint receptors (PD-1, CTLA-4) and reconstitution of antitumor immunity, emphasizing PDPN’s role as a key immunosuppressive regulator and highlighting CY12-RP2 as a promising candidate for immunotherapy. Here, CTLA4 is linked to melanoma.